Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane F Apperley

Showing results (81-90 of 195) with videos related to

Pageof 20
Sort By:
Haematologica|December 9, 2008
Severe events in donors after allogeneic hematopoietic stem cell donationJoerg Halter, Yoshihisa Kodera, Alvaro Urbano Ispizua, et al.
Transplant Immunology|November 17, 2007
Impact of HLA class I and class II DNA high-resolution HLA typing on clinical outcome in adult unrelated stem cell transplantation after in vivo T-cell depletion with alemtuzumabJolanta B Perz, Richard Szydlo, Ruhena Sergeant, et al.
Haematologica|August 24, 2011
Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failedAmr R Ibrahim, Richard E Clark, Tessa L Holyoake, et al.
BMC Medical Genomics|July 26, 2023
FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertionsPhilippa C May, Alistair G Reid, Mark E Robinson, et al.
British Journal of Haematology|April 7, 2009
Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?David Marin, Jamshid S Khorashad, Letizia Foroni, et al.
Blood Cancer Journal|February 28, 2018
Protease nexin-1 prevents growth of human B cell lymphoma via inhibition of sonic hedgehog signalingXiangke Xin, Yunchuan Ding, Ying Yang, et al.
Haematologica|March 30, 2019
MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemiaSimone Claudiani, Aoife Gatenby, Richard Szydlo, et al.
Blood|December 17, 2011
Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patientsDragana Milojkovic, Jane F Apperley, Gareth Gerrard, et al.
British Journal of Haematology|August 26, 2004
Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myelomaMarleen H C Bakkus, Yasmina Bouko, Diana Samson, et al.
Lancet (London, England)|August 29, 2003
Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfaDavid Marin, Sarah Marktel, Richard Szydlo, et al.
Pageof 20

Showing results (81-90 of 195) with videos related to

Sort By:
Pageof 20
Haematologica|December 9, 2008
Severe events in donors after allogeneic hematopoietic stem cell donationJoerg Halter, Yoshihisa Kodera, Alvaro Urbano Ispizua, et al.
Transplant Immunology|November 17, 2007
Impact of HLA class I and class II DNA high-resolution HLA typing on clinical outcome in adult unrelated stem cell transplantation after in vivo T-cell depletion with alemtuzumabJolanta B Perz, Richard Szydlo, Ruhena Sergeant, et al.
Haematologica|August 24, 2011
Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failedAmr R Ibrahim, Richard E Clark, Tessa L Holyoake, et al.
BMC Medical Genomics|July 26, 2023
FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertionsPhilippa C May, Alistair G Reid, Mark E Robinson, et al.
British Journal of Haematology|April 7, 2009
Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?David Marin, Jamshid S Khorashad, Letizia Foroni, et al.
Blood Cancer Journal|February 28, 2018
Protease nexin-1 prevents growth of human B cell lymphoma via inhibition of sonic hedgehog signalingXiangke Xin, Yunchuan Ding, Ying Yang, et al.
Haematologica|March 30, 2019
MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemiaSimone Claudiani, Aoife Gatenby, Richard Szydlo, et al.
Blood|December 17, 2011
Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patientsDragana Milojkovic, Jane F Apperley, Gareth Gerrard, et al.
British Journal of Haematology|August 26, 2004
Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myelomaMarleen H C Bakkus, Yasmina Bouko, Diana Samson, et al.
Lancet (London, England)|August 29, 2003
Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfaDavid Marin, Sarah Marktel, Richard Szydlo, et al.
Pageof 20